Back to top

Analyst Blog

Avanir Pharmaceuticals, Inc. (AVNR - Snapshot Report) reported first quarter fiscal 2013 net loss per share of 9 cents, wider than the Zacks Consensus Estimate of a loss of 8 cents, but narrower than the year-ago loss of 12 cents.

First quarter revenues soared 130% year over year to $16.5 million, marginally above the Zacks Consensus Estimate of $16 million.

Net revenues included Nuedexta revenue and royalty revenue from Abreva. Net Nuedexta revenues grew 20% sequentially to $14.9 million. Nuedexta is approved for the treatment of patients suffering from pseudobulbar affect (PBA).

Research and development expenses increased 77% year over year to $6.6 million. Selling, general and administrative expenses grew 5.2% year over year to $20.1 million.

Pipeline Update

The first-in-human phase I clinical study of AVP-786 which was initiated in Nov 2012 has completed the first stage. The study assessed the candidate’s single and multiple dose pharmacokinetics.

Meanwhile, AVP-923 is being studied for four indications, namely, Alzheimer's disease (phase II ongoing), central neuropathic pain in multiple sclerosis (phase II ongoing), levodopa-induced-dyskinesia (LID) in Parkinson's disease (PD) (phase II ongoing) and diabetic peripheral neuropathic pain (phase III ongoing).

Avanir plans to speed up the PRIME study (neuropathic pain related to multiple sclerosis) being conducted with AVP-923. Avanir expects to have top-line data from the PRIME study in the fourth quarter of calendar 2013.

Avanir currently carries a Zacks Rank #3 (Hold). Right now, Furiex Pharmaceuticals, Inc. , Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) and Valeant Pharma (VRX - Snapshot Report) look more attractive with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%